Hillhouse’s Overland builds momentum with second marquee China deal with Allogene

Allogene has found its gateway to China via a deal with Hillhouse-backed Overland that gives the newly launched China company its second partner and an allogeneic CAR T cell platform.

The news came a day after Overland Pharmaceuticals unveiled its first deal, under which it established a JV with ADC Therapeutics S.A. (NYSE:ADCT) to develop the Swiss company’s loncastuximab tesirine and three other pyrrolobenzodiazepine-based antibody-drug conjugates in Greater China and Singapore. Overland was co-founded by Hillhouse venture partners Hua Mu, the start-up’s interim CEO and CMO, and Ed Zhang, its COO and CBO. ...